Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS)

Immunoglobulin G (IgG) replacement therapy is a standard treatment for patients with primary immunodeficiency diseases (PIDs). Hizentra®, a 20% human subcutaneous IgG (SCIG), is approved for biweekly administration for PIDs. The aim of the multicenter IBIS study was to prospectively investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Vultaggio, Alessandra, Azzari, Chiara, Ricci, Silvia, Martire, Baldassarre, Palladino, Valentina, Gallo, Vera, Pecoraro, Antonio, Pignata, Claudio, Spadaro, Giuseppe, Graziani, Simona, Moschese, Viviana, Trizzino, Antonino, Boggia, Giorgio Maria, Matucci, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061090/
https://www.ncbi.nlm.nih.gov/pubmed/29951948
http://dx.doi.org/10.1007/s10875-018-0528-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061090/
https://www.ncbi.nlm.nih.gov/pubmed/29951948
http://dx.doi.org/10.1007/s10875-018-0528-5

Ejemplares similares